News / Taiwan / economic_daily
Greenyn Biotechnology Posts Record September Revenue with 31% YoY Growth
Health Technology · Biotechnology · economic_daily · 2026-10-07
6846
Greenyn Biotechnology reported a record-breaking September revenue of NT$77.51 million, up 31% year-on-year, driven by strong domestic and international demand.
What Happened
Record Revenue: Greenyn Biotechnology announced a consolidated revenue of NT$77.51 million for September, a 31% increase year-on-year and a new record for the month. The cumulative revenue for the first nine months reached NT$600 million, with the year-to-date decline continuing to narrow as the peak season approaches.
Market Momentum: Stronger-than-expected sales from major domestic brand clients and steady progress in overseas markets like Japan and Southeast Asia fueled the growth. The company's portfolio of proprietary ingredients and differentiated formulas continues to gain traction in the health supplement sector.
Global Expansion: Greenyn is actively expanding its footprint across Southeast Asia, Japan, South Korea, India, and North America. By leveraging its unique product offerings, the company aims to capture further market share in the global health and wellness industry.
International Outreach: Following its participation in Vitafoods Asia, Greenyn is set to attend Hi Japan and SupplySide Global in October. These key industry events are vital for the company to network with global partners and strengthen its international business presence.